Other equities research analysts have also recently issued reports about the stock. BidaskClub cut shares of Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Wedbush set a $20.00 price objective on shares of Plymouth Industrial Reit and gave the company a “buy” rating in a report on Monday, May 20th. Cantor Fitzgerald reissued a “buy” rating and issued a $71.00 price objective on shares of ExlService in a report on Monday, May 6th. Zacks Investment Research raised shares of Garrett Motion from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. Finally, HC Wainwright set a $55.00 target price on shares of Acer Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.80.
Shares of OMER stock traded up $0.04 during trading hours on Wednesday, hitting $15.49. The company’s stock had a trading volume of 237,955 shares, compared to its average volume of 524,451. The stock has a 50 day simple moving average of $16.23. Omeros has a 12-month low of $10.30 and a 12-month high of $27.00. The stock has a market cap of $756.51 million, a PE ratio of -6.98 and a beta of 3.04.
Several hedge funds and other institutional investors have recently modified their holdings of OMER. Rhumbline Advisers lifted its holdings in shares of Omeros by 73.3% in the fourth quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 30,547 shares in the last quarter. Miramar Capital LLC bought a new stake in Omeros during the fourth quarter worth about $192,000. Quad Cities Investment Group LLC raised its holdings in Omeros by 28.2% during the first quarter. Quad Cities Investment Group LLC now owns 13,650 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 3,000 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Omeros by 49.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after acquiring an additional 632,840 shares in the last quarter. Finally, Capital Impact Advisors LLC raised its holdings in Omeros by 42.6% during the fourth quarter. Capital Impact Advisors LLC now owns 136,570 shares of the biopharmaceutical company’s stock worth $1,581,000 after acquiring an additional 40,815 shares in the last quarter. Institutional investors own 52.12% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Read More: Hedge Funds Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.